Functional Characterization Experiment summary for ENCSR362QSD

doi:10.17989/ENCSR362QSD

Summary

Status
released
Assay
CRISPR screen (Control CRISPR screen)
Control type
control
Biosample summary
Homo sapiens HepG2 genetically modified using CRISPR (sgRNA), transduction 0 days after the sample was treated with 2 μg/mL puromycin for 2 days, 0.2 μg/mL puromycin for 2 days
Biosample Type
cell line
Perturbation type
interference
Replication type
isogenic
Description
Growth-based CRISPR screen targeting genomic regions near MYC and MYB genes.
Treatments
2 μg/mL puromycin (CHEBI:17939) for 2 days, 0.2 μg/mL puromycin (CHEBI:17939) for 2 days
Nucleic acid type
RNA
Size range
710-720
Strand specificity
unstranded
Controls
Elements references

Attribution

ENCODE4 project
Lab
Bing Ren, UCSD
Award
UM1HG009402 (Yin Shen, UCSF)
Project
ENCODE
Aliases
bing-ren:BC19E_D0_HepG2
Date submitted
January 31, 2020
Date released
August 6, 2020

Isogenic replicates

Isogenic replicate
Technical replicate
Summary
Biosample
Modifications
Library
21HepG2 cell line genetically modified (insertion) using transduction, genetically modified (interference) using CRISPR (sgRNA) 0 days after the sample was treated with 2 μg/mL puromycin for 2 days, 0.2 μg/mL puromycin for 2 daysENCBS613DXGENCGM554RTS, ENCGM353IMQENCLB313DNY
11HepG2 cell line genetically modified (insertion) using transduction, genetically modified (interference) using CRISPR (sgRNA) 0 days after the sample was treated with 2 μg/mL puromycin for 2 days, 0.2 μg/mL puromycin for 2 daysENCBS468YPTENCGM554RTS, ENCGM353IMQENCLB860YHP